Compare · NTRA vs PMD
NTRA vs PMD
Side-by-side comparison of Natera Inc. (NTRA) and Psychemedics Corporation (PMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and PMD operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $47.01B, about 1176.5x PMD ($40.0M).
- NTRA has hit the wire 8 times in the past 4 weeks while PMD has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 0 for PMD).
- Company
- Natera Inc.
- Psychemedics Corporation
- Price
- -
- -
- Market cap
- $47.01B
- $40.0M
- 1M return
- +4.38%
- -
- 1Y return
- +87.93%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.
Latest NTRA
- UBS resumed coverage on Natera with a new price target
- Rothschild & Co Redburn initiated coverage on Natera with a new price target
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $5,917,907 worth of shares (18,160 units at $325.88) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 110,859 units (SEC Form 4) to satisfy withholding tax
- CEO AND PRESIDENT Chapman Steven Leonard sold $545,041 worth of shares (1,698 units at $320.99) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 98,199 units (SEC Form 4)
- New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
- PRESIDENT, CHIEF BUS. OFFICER Fesko John was granted 20,000 shares and sold $2,095,411 worth of shares (6,517 units at $321.53) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 197,257 units (SEC Form 4) (tax liability)
- Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
- Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Latest PMD
- Psychemedics Releases 2026 Education Insights Report
- Psychemedics Releases 2026 Workforce Insights Report
- Psychemedics Releases 2025 Workforce Insights Report
- Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights
- SEC Form 15-12G filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)
- SEC Form 25 filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation
- Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)